All News

Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise.

If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation yesterday at Chandler Chicco’s Pioneers in Digital Health conference.

After almost nine years of working at Pharm Exec magazine, it’s time for me to move on.

While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.

I’ve been doing this digital thing for some time now. I’ve been part of and witnessed many changes in our digital world.

Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.

The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will work.

Worried they might get taken for a ride, university tech transfer offices are beginning to hire ex-pharma and biotech personnel to help negotiate deals with industry.

Medication adherence is an ongoing and serious problem; according to the Center for Health Transformation, the annual cost of patients not taking their medicines as prescribed is nearly $300 billion, with approximately 125,000 patients dying each year due to poor adherence-that’s 342 people every day.

Provisions in the Affordable Care Act (ACA) drove out-of-pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011, according to research published on Wednesday.

Come Rain or Shine

Amid one of the most divisive eras in our nation’s political history, one thing we can all pretty much agree on is the fact that our stalled economic engine needs a jumpstart.

This June, Californians will be asked whether cigarette smokers should subsidize research to treat diseases related to smoking cigarettes.

A critical drug that has experienced shortages is Genzyme’s Fabrazyme (agalsidase beta), the only enzyme replacement therapy approved in the US for Fabry disease.

UK pharma and biopharma was quick to respond positively to the Chancellor of the Exchequer’s annual Budget speech last week, despite some industry disappointment at a fiscal program widely derided as safe, neutral, and, in Andrew Goodwin of Ernst & Young’s words, “one of the most predictable” of recent times.

In judging the Prometheus patents invalid, the Supreme Court may have shown its hand on the upcoming Myriad Genetics case.

In honor of World TB Day March 24, research organizations and international health agencies announced important advances in the development of new therapies for stemming the spread of increasingly lethal tuberculosis strains.

The UK Financial Times this week (March 18) flagged up data from Withers & Rogers, a London-based IP firm, showing how the numbers of patent filings from the ten leading pharma companies has dropped in recent years.

Over a hundred public companies, dozens of clinicians, and several regulators participated in investment firm Leerink Swann’s 2012 Healthcare Conference in mid-February.

One of the key reputational assets of Big Pharma is the patient assistance program [PAP], which provides patented innovative medicines to needy patients for free or at a nominal charge – it’s the industry’s own branded version of the social safety net

We thank you and your editorial staff for publishing the article titled ‘How to Choose a Medical Animator’ in the 1 February issue of Pharmaceutical Executive

Merck KGaA has announced measures intended to reduce costs and increase efficiency to ensure the long-term success of its business model

SAS’s Brad Sitler talks about the importance of incremental sales, customer proximity, and anticipating a compensation model based on health outcomes

Biotechs in Colorado, US, are enjoying a windfall of funding from Venture Capitalists who have to date invested $66.

A couple of years ago I spoke at a Life Sciences Forum organized by Oracle. The audience was 100-percent life science and IT professionals, but I spoke about the magazine business.

The Supreme Court will open up deliberations on the constitutionality of three important parts of healthcare reform (HCR) this month

Leading in Emerging Markets